Dobrodeeva, V.S.,
Shnayder, N.A.,
Novitsky, M.A.,
Asadullin, A.R.,
Vaiman, E.E.,
Petrova, M.M.,
Limankin, O.V.,
Neznanov, N.G.,
Garganeeva, N.P.,
Nasyrova, R.F. (2022) diseases with a high rate of mortality in patients with SSDs. Neuropeptide Y receptor Y5 (NPY5R) is known
LEGG, L.A.,
TILNEY, R.,
HSIEH, C.F.,
WU, S.,
LUNDSTRÖM, E.,
RUDBERG, A.S.,
KUTLUBAEV, M.A.,
DENNIS, M.,
MEAD, G.E.,
SOLEIMANI, B.,
BARUGH, A.,
HACKETT, M.L.,
HANKEY, G.J (2019) required participants to have depression to enter the trial. The
duration, drug, and dose varied between